PL3487851T3 - Pochodne aminopirydyny i ich zastosowanie jako selektywnych inhibitorów alk-2 - Google Patents

Pochodne aminopirydyny i ich zastosowanie jako selektywnych inhibitorów alk-2

Info

Publication number
PL3487851T3
PL3487851T3 PL17830463T PL17830463T PL3487851T3 PL 3487851 T3 PL3487851 T3 PL 3487851T3 PL 17830463 T PL17830463 T PL 17830463T PL 17830463 T PL17830463 T PL 17830463T PL 3487851 T3 PL3487851 T3 PL 3487851T3
Authority
PL
Poland
Prior art keywords
inhibitors
aminopyridine derivatives
selective alk
alk
selective
Prior art date
Application number
PL17830463T
Other languages
English (en)
Polish (pl)
Inventor
Jialiang LI
Luca Arista
Sreehari BABU
Jianwei BIAN
Kai CUI
Michael Patrick Dillon
Rene Lattmann
Lv LIAO
Dimitrios Lizos
Rita Ramos
Nikolaus Johannes Stiefl
Thomas Ullrich
Peggy USSELMANN
Xiaoyang Wang
Liladhar Murlidhar Waykole
Sven Weiler
Yubo ZHANG
Yizong ZHOU
Tingying ZHU
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3487851T3 publication Critical patent/PL3487851T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL17830463T 2016-07-20 2017-07-18 Pochodne aminopirydyny i ich zastosowanie jako selektywnych inhibitorów alk-2 PL3487851T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
EP17830463.0A EP3487851B1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
PL3487851T3 true PL3487851T3 (pl) 2022-04-11

Family

ID=60991950

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17830463T PL3487851T3 (pl) 2016-07-20 2017-07-18 Pochodne aminopirydyny i ich zastosowanie jako selektywnych inhibitorów alk-2
PL21202619.9T PL3971177T3 (pl) 2016-07-20 2017-07-18 Pochodne aminopirydyny i ich zastosowanie jako selektywne inhibitory alk-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21202619.9T PL3971177T3 (pl) 2016-07-20 2017-07-18 Pochodne aminopirydyny i ich zastosowanie jako selektywne inhibitory alk-2

Country Status (25)

Country Link
US (4) US10710980B2 (enExample)
EP (3) EP3971177B1 (enExample)
JP (5) JP7030776B2 (enExample)
KR (7) KR102359707B1 (enExample)
CN (2) CN109641871B (enExample)
AR (1) AR109108A1 (enExample)
AU (5) AU2017298187B2 (enExample)
CY (1) CY1124967T1 (enExample)
DK (2) DK3487851T3 (enExample)
EA (2) EA037520B1 (enExample)
ES (2) ES2902521T3 (enExample)
FI (1) FI3971177T3 (enExample)
HR (2) HRP20211868T1 (enExample)
HU (2) HUE067992T2 (enExample)
LT (2) LT3971177T (enExample)
MX (2) MX388518B (enExample)
PL (2) PL3487851T3 (enExample)
PT (2) PT3971177T (enExample)
RS (2) RS62819B1 (enExample)
RU (1) RU2747318C2 (enExample)
SI (2) SI3971177T1 (enExample)
SM (2) SMT202100723T1 (enExample)
TW (5) TWI712598B (enExample)
UY (1) UY37331A (enExample)
WO (1) WO2018014829A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
IL298767A (en) * 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
KR102913358B1 (ko) * 2020-10-29 2026-01-14 주식회사 엘지화학 중수소화 화합물의 분석방법, 소자 제조용 중수소화 화합물의 선별방법 및 전자 소자의 제조방법
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) * 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
JP4198183B2 (ja) 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
EP2069313A2 (en) 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
EP2270229A1 (en) 2006-09-12 2011-01-05 The General Hospital Corporation Inhibitors of bone morphogenetic protein (BMP) signalling for therapeutical purposes
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
AR084731A1 (es) 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) * 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
PT2970205T (pt) * 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
EP3344613B1 (en) 2015-08-31 2020-03-04 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
EP3488532B1 (en) 2016-07-20 2025-02-19 Qorvo US, Inc. Method for tuning an antenna with a dvc
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
KR20240074904A (ko) 2024-05-28
MX2021014852A (es) 2022-01-18
TWI851226B (zh) 2024-08-01
PT3971177T (pt) 2024-07-30
HUE057328T2 (hu) 2022-05-28
CN114014844A (zh) 2022-02-08
JP2023089012A (ja) 2023-06-27
JP7834830B2 (ja) 2026-03-24
AR109108A1 (es) 2018-10-31
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10
DK3971177T3 (da) 2024-07-15
TWI712598B (zh) 2020-12-11
RU2021111037A (ru) 2021-05-13
DK3487851T3 (da) 2021-12-20
EA201990343A1 (ru) 2019-06-28
JP2025032086A (ja) 2025-03-11
TWI806385B (zh) 2023-06-21
US10947218B2 (en) 2021-03-16
AU2021201424A1 (en) 2021-03-25
KR20240155367A (ko) 2024-10-28
KR102719881B1 (ko) 2024-10-23
JP7253086B2 (ja) 2023-04-05
TWI755255B (zh) 2022-02-11
EA202190285A1 (ru) 2021-08-31
LT3487851T (lt) 2021-12-27
KR20210094138A (ko) 2021-07-28
RS62819B1 (sr) 2022-02-28
EP3971177B1 (en) 2024-06-26
JP2022078137A (ja) 2022-05-24
MX388518B (es) 2025-03-19
AU2023200265B2 (en) 2024-08-15
KR20190026917A (ko) 2019-03-13
ES2984746T3 (es) 2024-10-30
TW201805277A (zh) 2018-02-16
EA037520B1 (ru) 2021-04-07
BR112019000941A2 (pt) 2019-04-30
EP4442317A2 (en) 2024-10-09
US20210155606A1 (en) 2021-05-27
EP3487851B1 (en) 2021-10-20
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
US20190161474A1 (en) 2019-05-30
US20260116869A1 (en) 2026-04-30
KR20220143770A (ko) 2022-10-25
US10710980B2 (en) 2020-07-14
AU2017298187A1 (en) 2018-12-20
TWI925178B (zh) 2026-05-11
EP3487851A4 (en) 2019-12-25
PL3971177T3 (pl) 2024-10-28
TW202336011A (zh) 2023-09-16
RU2021111037A3 (enExample) 2022-02-10
KR102667331B1 (ko) 2024-05-21
KR102454129B1 (ko) 2022-10-14
JP7030776B2 (ja) 2022-03-07
FI3971177T3 (fi) 2024-07-30
TW202509017A (zh) 2025-03-01
RU2019104609A3 (enExample) 2020-09-30
KR20220021023A (ko) 2022-02-21
RU2747318C2 (ru) 2021-05-04
HRP20241015T1 (hr) 2024-11-08
KR102359707B1 (ko) 2022-02-09
TW202134228A (zh) 2021-09-16
HRP20211868T1 (hr) 2022-03-04
US20200299265A1 (en) 2020-09-24
US12466808B2 (en) 2025-11-11
JP2026120530A (ja) 2026-07-22
PT3487851T (pt) 2022-01-07
RU2019104609A (ru) 2020-08-20
CN114014844B (zh) 2024-10-01
KR102281550B1 (ko) 2021-07-27
AU2023200265A1 (en) 2023-02-16
LT3971177T (lt) 2024-08-26
CN109641871B (zh) 2021-10-22
EP3971177A1 (en) 2022-03-23
MX2019000837A (es) 2019-07-04
EP4442317A3 (en) 2025-01-01
UY37331A (es) 2018-02-28
JP7584553B2 (ja) 2024-11-15
TW202220969A (zh) 2022-06-01
CA3030332A1 (en) 2018-01-25
KR102559539B1 (ko) 2023-07-26
AU2024205058A1 (en) 2024-08-15
CY1124967T1 (el) 2023-01-05
SMT202400335T1 (it) 2024-09-16
JP2019521167A (ja) 2019-07-25
ES2902521T3 (es) 2022-03-28
SI3971177T1 (sl) 2024-10-30
AU2019246857B2 (en) 2020-12-24
CN109641871A (zh) 2019-04-16
HUE067992T2 (hu) 2024-12-28
AU2019246857A1 (en) 2019-10-31
RS66041B1 (sr) 2024-11-29
WO2018014829A1 (en) 2018-01-25
EP3487851A1 (en) 2019-05-29
AU2021201424B2 (en) 2022-10-20
KR20230117248A (ko) 2023-08-07

Similar Documents

Publication Publication Date Title
IL258081B (en) Benzimidazole history and their use
ZA201801196B (en) Nicotinamide mononucleotide derivatives and their uses
SG11201912267SA (en) Nicotinamide riboside derivatives and their uses
IL253656A0 (en) Mono- and polyazanephthalene modified histories and their use
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
IL247252B (en) History of isoquinoline and its use
IL252560B (en) Heterocyclic derivatives and their uses
IL259150B (en) Pyrimidine derivative and use thereof
IL260366B (en) The history of quinoline-2-one, their preparation and their use
SI3971177T1 (sl) Derivati aminopiridina in njihova uporaba kot selektivni zaviralci ALK-2
IL261643B (en) Piperidine derivatives, their preparation and use
ZA201701066B (en) Pyridine derivatives and anti-mycobacterial use thereof
PT3398598T (pt) Derivado de sulfonamida e método de preparação e utilização do mesmo
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
SG11201701043UA (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
ZA201705530B (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
IL261645A (en) History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
IL262597B (en) Piperidinyl derivatives, their preparation and use
HK40007022A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
HK40029730A (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
GB201404330D0 (en) Selective glycosidase inhibitors and uses thereof